Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Quadrivalent seasonal influenza vaccine GSK2321138A · 1 trial · 1 indication
Attack rate (AR) was defined as the number/percentage of subjects with at least 1 RT-PCR confirmed influenza event.
Attack rate (AR) was defined as the number/percentage of subjects with at least 1 RT-PCR confirmed influenza event.
| Arm | Type | Description |
|---|---|---|
| D-QIV | EXPERIMENTAL | Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A). |
| Control | ACTIVE_COMPARATOR | In function of their age and D-QIV-vaccine status, subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®). |
| Name | Type | Description |
|---|---|---|
| Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A | BIOLOGICAL | Intramuscular injection |
| Havrix Junior | BIOLOGICAL | Intramuscular injection administered to subjects aged 12 months or older |
| Prevenar 13 | BIOLOGICAL | Intramuscular injection administered to subjects less than 12 months of age |
| Varivax/ProVarivax | BIOLOGICAL | Intramuscular injection administered to subjects more than 12 months of age |
| Varilrix | BIOLOGICAL | Subcutaneous injection administered to subjects more than 12 months of age |
Inclusion Criteria: * Subjects who the investigator believes that their parents/Legally Acceptable Representative (LARs) can and will comply with the requirements of the protocol. * A male or female between, and including, 6 and 35 months of age at the time of first vaccination; children are eligib...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Cell-based Trivalent Split Influenza Virus Vaccine, Egg-based Trivalent Split Influenza Virus Vaccine |
Quadrivalent seasonal influenza vaccine GSK2321138A is an investigational vaccine developed by GSK plc for the prevention of influenza. It is designed to protect against four influenza virus strains, which is what quadrivalent means. It is a vaccine candidate that has been studied in children as young as 6 months old.
Quadrivalent seasonal influenza vaccine GSK2321138A is being developed for the prevention of influenza, a contagious respiratory illness caused by influenza viruses. The clinical program evaluated it in children, with study participants as young as 6 months of age. It is intended for active immunization against seasonal influenza.
Quadrivalent seasonal influenza vaccine GSK2321138A is developed by GSK plc, which trades under the ticker GSK. GSK Biologicals, the company's vaccines business, sponsored the clinical study of this candidate influenza vaccine. GSK2321138A is the internal GSK code for the candidate.
Quadrivalent seasonal influenza vaccine GSK2321138A has been studied in a Phase 3 clinical trial. It is an investigational vaccine candidate and is not described as approved. The Phase 3 study has been completed, and no trials of this candidate are currently listed as active.
Quadrivalent seasonal influenza vaccine GSK2321138A was evaluated in the Phase 3 trial NCT01439360, titled An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children. The completed study enrolled 12,046 participants across 13 countries, including Bangladesh, Belgium, Czechia, the Dominican Republic, Honduras, India, Lebanon, the Philippines, Poland, Spain, Thailand, Turkey and the United Kingdom.
Yes. Quadrivalent seasonal influenza vaccine GSK2321138A is also known as quadrivalent seasonal influenza vaccine (Flu D-QIV) GSK2321138A. Flu D-QIV is a shorthand label for the same GSK candidate vaccine, and GSK2321138A is the company's internal identifier. Searches for either name refer to the same investigational influenza vaccine.